A Novel HAGE/WT1-ImmunoBody(®) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone

Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA) DDX43 (HAGE) and/or the oncogene Wilms’ tumour (WT1). Here we demonstrate that HAGE/WT1-ImmunoBody(®) vaccines derived T-cells can kill ex-vivo human CML cell lines expressing these antigens and significantly delay B16...

Descripción completa

Detalles Bibliográficos
Autores principales: Almshayakhchi, Rukaia, Nagarajan, Divya, Vadakekolathu, Jayakumar, Guinn, Barbara-Ann, Reeder, Stephen, Brentville, Victoria, Metheringham, Rachael, Pockley, A. Graham, Durrant, Lindy, McArdle, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273701/
https://www.ncbi.nlm.nih.gov/pubmed/34262856
http://dx.doi.org/10.3389/fonc.2021.636977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273701/
https://www.ncbi.nlm.nih.gov/pubmed/34262856
http://dx.doi.org/10.3389/fonc.2021.636977

Ejemplares similares